+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bipolar Disorder Therapeutics Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • December 2023
  • Region: Global
  • The Business Research Company
  • ID: 5751825
Bipolar disorder therapeutics consist of medications such as mood stabilizers, antidepressants, antipsychotics, and psychological counseling aimed at controlling symptoms associated with bipolar disorders. These therapeutics play a crucial role in the treatment and management of bipolar disorders.

The primary categories of drugs within bipolar disorder therapeutics include mood stabilizers, antipsychotic drugs, antidepressant drugs, and other medications. Mood stabilizers constitute a class of drugs specifically designed for the management and treatment of bipolar disorders. Various mechanisms are employed, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These drugs are commonly available through hospital pharmacies, retail pharmacies, and online pharmacies.

The bipolar disorder therapeutics market research report is one of a series of new reports that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.09 billion in 2023 to $7.53 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period of bipolar disorder therapeutics can be attributed to factors such as increased investment in medical research and development, a rise in healthcare expenditure, an increase in the prevalence of mental health disorders, and a growing emphasis on patient advocacy.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.46 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The forecasted growth in bipolar disorder therapeutics can be attributed to factors such as the increasing prevalence of bipolar disorder, government initiatives, the expansion of healthcare infrastructure, and the growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, integration of digital health solutions, the development of innovative medications, preventive interventions, and the use of neuroimaging and biomarkers for diagnosis and treatment monitoring.

The escalating prevalence of bipolar disorder is anticipated to drive the growth of the bipolar disorder therapeutics market. Characterized by disabling mood swings and associated symptoms such as irregular sleep patterns, low motivation, and a loss of interest in daily activities, bipolar disorder poses a growing burden due to population growth and aging. This demographic shift is contributing to an increased demand for bipolar disorder therapeutics. In 2021, the Depression and Bipolar Support Alliance reported that approximately 5.7 million adult Americans, constituting 2.6% of the U.S. population, were affected by bipolar disorder. The onset of bipolar disorder typically occurs at a median age of 25, with more than two-thirds of individuals with the disorder having at least one relative similarly affected. Consequently, the rising prevalence of bipolar disorder is a key driver propelling the growth of the bipolar disorder therapeutics market.

The growing demand for psychological counseling is expected to significantly contribute to the expansion of the bipolar disorder therapeutics market. Psychological counseling, a form of therapy aimed at improving mental health and enhancing overall quality of life, plays a crucial role in managing symptoms of bipolar disorder. Psychotherapy helps individuals identify triggers for bipolar episodes and equips them with coping mechanisms for stressors. According to The Centers for Disease Control and Prevention (CDC), from 2019 to 2021, there was an increase in the percentages of both men and women aged 18–44 in the U.S. who received any mental health treatment in the past 12 months. The surge in demand for psychological counseling underscores a critical aspect of bipolar disorder therapeutics, driving the market forward.

A notable trend in the bipolar disorder therapeutics market is the emergence of strategic partnerships among major companies in the sector. Companies operating in the bipolar disorder therapeutics space are actively seeking partnerships to strengthen their positions and enhance their capabilities. For example, in October 2021, Mindpax Inc., a Germany-based digital technology company in the bipolar disorder therapeutics market, partnered with Eversana Life Science Services LLC, a U.S.-based life sciences company. This collaboration aims to develop remote clinical assessments and targeted digital therapy to improve patient outcomes and offer personalized therapeutic interventions for individuals with bipolar disorder. Another significant partnership occurred in November 2020, with Biogen, a U.S.-based biotechnology company, joining forces with Sage Therapeutics, a company specializing in novel therapies for bipolar disorder and other psychiatric diseases. This partnership focuses on the commercialization of zuranolone (SAGE-217) for postpartum depression, major depressive disorder, and other psychiatric conditions, showcasing the trend of strategic collaborations in the bipolar disorder therapeutics market.

Leading companies in the Bipolar Disorder Therapeutics and related market are actively engaged in the development of new treatments specifically targeting depressive episodes associated with bipolar I or II disorder. Bipolar depression represents the most prevalent and severe clinical manifestation among bipolar disorders, often associated with poorer prognosis, longer duration, and increased recurrence compared to manic/hypomanic episodes. An illustrative example is Intra-Cellular Therapies, Inc. (ITCI), a U.S.-based biopharmaceutical company. In December 2021, ITCI announced the U.S. FDA approval for 'CAPLYTA,' a medication designed for the treatment of depressive episodes linked to bipolar I or II disorder in adults. CAPLYTA is approved for use both as monotherapy and as adjunctive therapy with lithium or valproate, exemplifying the industry's commitment to addressing the critical and prevalent aspects of bipolar disorder therapeutics.

In June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, made a strategic move by acquiring the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd., the terms of which were undisclosed. This acquisition, facilitated by Brain Therapeutics, aims to broaden Neuraxpharm Group's therapeutic product portfolio in Greece and Europe. The agreement positions Neuraxpharm Group to leverage its expertise in the central nervous system (CNS) field, ensuring that Lazap reaches a wider audience. Lyofin Ltd., the Greek pharmaceutical company, is a key player in this collaboration, contributing to the expansion of Neuraxpharm Group's offerings in the CNS therapeutic domain. This strategic move reflects the industry's dedication to meeting healthcare demands by enhancing its product portfolio and geographical reach.

Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd., H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan PLC, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

North America was the largest region in the bipolar disorder therapeutics market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Bipolar Disorder Therapeutics Market Characteristics3. Bipolar Disorder Therapeutics Market Trends And Strategies
4. Bipolar Disorder Therapeutics Market - Macro Economic Scenario
4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market
5. Global Bipolar Disorder Therapeutics Market Size and Growth
5.1. Global Bipolar Disorder Therapeutics Market Drivers and Restraints
5.1.1. Drivers Of The Market
5.1.2. Restraints Of The Market
5.2. Global Bipolar Disorder Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Bipolar Disorder Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Bipolar Disorder Therapeutics Market Segmentation
6.1. Global Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Mood Stabilizers
Antipsychotic Drugs
Antidepressant Drugs
Other Drugs
6.2. Global Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Selective Serotonin Reuptake Inhibitors
Serotonin-norepinephrine Reuptake Inhibitors
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Benzodiazepines
Beta-Blockers
Other Mechanisms
6.3. Global Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
7. Bipolar Disorder Therapeutics Market Regional And Country Analysis
7.1. Global Bipolar Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Bipolar Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Bipolar Disorder Therapeutics Market
8.1. Asia-Pacific Bipolar Disorder Therapeutics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Bipolar Disorder Therapeutics Market
9.1. China Bipolar Disorder Therapeutics Market Overview
9.2. China Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Bipolar Disorder Therapeutics Market
10.1. India Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Bipolar Disorder Therapeutics Market
11.1. Japan Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Bipolar Disorder Therapeutics Market
12.1. Australia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Bipolar Disorder Therapeutics Market
13.1. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Bipolar Disorder Therapeutics Market
14.1. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Bipolar Disorder Therapeutics Market
15.1. Western Europe Bipolar Disorder Therapeutics Market Overview
15.2. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Bipolar Disorder Therapeutics Market
16.1. UK Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Bipolar Disorder Therapeutics Market
17.1. Germany Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Bipolar Disorder Therapeutics Market
18.5. France Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Bipolar Disorder Therapeutics Market
19.9. Italy Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Bipolar Disorder Therapeutics Market
20.13. Spain Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Bipolar Disorder Therapeutics Market
21.1. Eastern Europe Bipolar Disorder Therapeutics Market Overview
21.2. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Bipolar Disorder Therapeutics Market
22.1. Russia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Bipolar Disorder Therapeutics Market
23.1. North America Bipolar Disorder Therapeutics Market Overview
23.2. North America Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Bipolar Disorder Therapeutics Market
24.1. USA Bipolar Disorder Therapeutics Market Overview
24.2. USA Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Bipolar Disorder Therapeutics Market
25.1. Canada Bipolar Disorder Therapeutics Market Overview
25.2. Canada Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Bipolar Disorder Therapeutics Market
26.1. South America Bipolar Disorder Therapeutics Market Overview
26.2. South America Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Bipolar Disorder Therapeutics Market
27.1. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Bipolar Disorder Therapeutics Market
28.1. Middle East Bipolar Disorder Therapeutics Market Overview
28.2. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Bipolar Disorder Therapeutics Market
29.1. Africa Bipolar Disorder Therapeutics Market Overview
29.2. Africa Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Bipolar Disorder Therapeutics Market Competitive Landscape And Company Profiles
30.1. Bipolar Disorder Therapeutics Market Competitive Landscape
30.2. Bipolar Disorder Therapeutics Market Company Profiles
30.2.1. AbbVie Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Pfizer Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Astellas Pharma Inc
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. AstraZeneca PLC
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Bristol-Myers Squibb
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Bipolar Disorder Therapeutics Market Competitive Benchmarking32. Global Bipolar Disorder Therapeutics Market Competitive Dashboard33. Key Mergers And Acquisitions In The Bipolar Disorder Therapeutics Market
34. Bipolar Disorder Therapeutics Market Future Outlook and Potential Analysis
34.1 Bipolar Disorder Therapeutics Market In 2028 - Countries Offering Most New Opportunities
34.2 Bipolar Disorder Therapeutics Market In 2028 - Segments Offering Most New Opportunities
34.3 Bipolar Disorder Therapeutics Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer

Executive Summary

Bipolar Disorder Therapeutics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bipolar disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • All data from the report will also be delivered in an excel dashboard format.

Description:

Where is the largest and fastest growing market for bipolar disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

  • Markets Covered: 1) By Drug Class: Mood Stabilizers; Antipsychotic Drugs; Antidepressant Drugs; Other Drugs 2) By Mechanism: Selective Serotonin Reuptake Inhibitors; Serotonin-norepinephrine Reuptake Inhibitors; Tricyclic Antidepressants; Monoamine Oxidase Inhibitors; Benzodiazepines; Beta-Blockers; Other Mechanisms 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Astellas Pharma Inc; AstraZeneca PLC; Bristol-Myers Squibb
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • GlaxoSmithKline PLC
  • Januaryssen Pharmaceuticals
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Validus Pharmaceuticals
  • Eli Lilly and Company
  • Gedeon Richter PLC.
  • Sumitomo Pharma Co. Ltd
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals
  • Sanofi S.A.
  • Lundbeck A/S
  • Allergan plc
  • Takeda Pharmaceutical Company Limited
  • Sunovion Pharmaceuticals Inc.
  • Alkermes plc
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Celon Pharma SA
  • NeuroRx Inc.
  • IntraCellular Therapies Inc.
  • Sumitomo Pharma Co. Ltd.
  • Vanda Pharmaceuticals Inc.
  • Sage Therapeutics Inc.

Methodology

Loading
LOADING...